PMID- 17827264 OWN - NLM STAT- MEDLINE DCOM- 20080131 LR - 20220318 IS - 0363-6135 (Print) IS - 0363-6135 (Linking) VI - 293 IP - 6 DP - 2007 Dec TI - Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival. PG - H3311-6 AB - We hypothesized that pretreatment of an infarcted heart by mechanical transmyocardial revascularization (TMR) before transplantation of bone marrow cells (BMCs) or BMC-expressing angiogenic growth factors would increase transplanted BMC survival and enhance myocardial repair. Female Lewis rats underwent coronary ligation 3 wk before creation of 10 needle TMR channels (3 groups) or no TMR (3 groups), followed by transplantation of 3 x 10(6) male donor BMCs, BMC transfected with vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and insulin-like growth factor-1 (IGF-1) (BMC + VBI), or medium alone. At 1, 3, and 7 days, we evaluated transplanted cell survival, vascular densities, and left ventricular (LV) function (N = 4 per group x 6 groups x 3 time points). At 3 days, vascular densities in the scar were increased by TMR + BMC + VBI and by BMC + VBI (P < 0.05), and at 7 days, vascular densities were greatest in rats receiving TMR + BMC + VBI (P < 0.05). Transplanted cell survival at 3 and 7 days was increased by TMR and by BMC + VBI. Combined therapy with TMR + BMC + VBI resulted in the greatest cell survival at 3 days (P < 0.05) versus BMC. After 7 days, LV ejection fraction (LVEF) was lowest in rats receiving neither BMC nor TMR and greatest in rats receiving TMR + BMC + VBI (P = 0.004). We concluded that mechanical pretreatment of infarcted myocardium by TMR enhances the effect of subsequent cell-based gene therapy on transplanted cell survival, angiogenesis, and LV function. Scar pretreatment with TMR combined with cell-based multigene therapy may maximize myocardial repair. FAU - Spiegelstein, Dan AU - Spiegelstein D AD - Division of Cardiovascular Surgery, Toronto General Hospital, University Health Network, 200 Elizabeth Street, Toronto, Ontario, Canada. FAU - Kim, Christopher AU - Kim C FAU - Zhang, Yaoguang AU - Zhang Y FAU - Li, Guangming AU - Li G FAU - Weisel, Richard D AU - Weisel RD FAU - Li, Ren-Ke AU - Li RK FAU - Yau, Terrence M AU - Yau TM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070907 PL - United States TA - Am J Physiol Heart Circ Physiol JT - American journal of physiology. Heart and circulatory physiology JID - 100901228 RN - 0 (Angiogenic Proteins) RN - 0 (Vascular Endothelial Growth Factor A) RN - 103107-01-3 (Fibroblast Growth Factor 2) RN - 67763-96-6 (Insulin-Like Growth Factor I) SB - IM MH - Angiogenic Proteins/genetics/*metabolism MH - Animals MH - Bone Marrow Cells/*metabolism MH - *Bone Marrow Transplantation MH - Cell Survival MH - Cells, Cultured MH - Combined Modality Therapy MH - Coronary Vessels/*metabolism/pathology/physiopathology/surgery MH - Disease Models, Animal MH - Female MH - Fibroblast Growth Factor 2/metabolism MH - Genetic Therapy/*methods MH - Insulin-Like Growth Factor I/metabolism MH - Ligation MH - Male MH - Myocardial Infarction/genetics/metabolism/pathology/physiopathology/surgery/*therapy MH - Myocardial Revascularization/*methods MH - Myocardium/*metabolism/pathology MH - Neovascularization, Physiologic MH - Rats MH - Rats, Inbred Lew MH - Stress, Mechanical MH - Stroke Volume MH - Time Factors MH - Transfection MH - Vascular Endothelial Growth Factor A/metabolism MH - Ventricular Function, Left EDAT- 2007/09/11 09:00 MHDA- 2008/02/01 09:00 CRDT- 2007/09/11 09:00 PHST- 2007/09/11 09:00 [pubmed] PHST- 2008/02/01 09:00 [medline] PHST- 2007/09/11 09:00 [entrez] AID - 00178.2007 [pii] AID - 10.1152/ajpheart.00178.2007 [doi] PST - ppublish SO - Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3311-6. doi: 10.1152/ajpheart.00178.2007. Epub 2007 Sep 7.